



ERIC HOLCOMB, GOVERNOR  
STATE OF INDIANA

*Office of Medicaid Policy and Planning*  
MS 07, 402 W. WASHINGTON STREET, ROOM W382  
INDIANAPOLIS, IN 46204-2739

## MEETING AGENDA AND PUBLIC NOTIFICATION

Therapeutics Committee

May 5, 2023

11:00 A.M. EST

### **Hybrid Meeting**

Conference Center Room B

Indiana State Government Center South

Virtual Meeting Information Below

1. Call to Order-Chair
2. Preferred Drug List: Therapeutic Class Re-Review – Discussion and Recommendations
3. Preferred Drug List: Therapeutic Class Re-Review
  - a. CNS and Others
    - i. Agents for the Treatment of Opiate Addiction
    - ii. Antiemetic/Antivertigo Agents
    - iii. Antiseizure Agents
    - iv. Gastroprotective Agents
    - v. Movement Disorder Agents
    - vi. Narcotic Antitussives and Combinations
    - vii. Narcotics
    - viii. Skeletal Muscle Relaxants
    - ix. Smoking Deterrent Agents
  - b. Dermatologic Agents
    - i. Acne Agents
    - ii. Antipsoriatics
  - c. Endocrine



- i. Anaphylaxis Agents
  - ii. Bone Formation Stimulating Agents
  - iii. Bone Resorption Inhibitors
  - iv. DPP-4 Inhibitors and Combination Agents
  - v. GLP-1 Receptor Agonists and Combinations
  - vi. Glucagon Agents
  - vii. Growth Hormones
  - viii. Injectable Hypoglycemics, Insulin
  - ix. Miscellaneous Oral Antidiabetic Agents
  - x. SGLT2 Inhibitors and Combinations
  - xi. Testosterones
- d. Estrogen and Related Agents
- i. Estrogen and Related Agents
  - ii. Contraceptives
- e. Gastrointestinal Agents
- i. Anti-ulcer Agents
  - ii. *H.Pylori* Agents
  - iii. H<sub>2</sub> Receptor Antagonists
  - iv. Laxatives and Cathartics
  - v. Pancreatic Enzymes
  - vi. Proton Pump Inhibitors
  - vii. Ulcerative Colitis Agents
- f. Genitourinary Agents
- i. Benign Prostatic Hypertrophy Agents
  - ii. Urinary Tract Antispasmodic/Anti-Incontinence Agents
- g. Hematologic Agents
- i. Direct Oral Anticoagulants
  - ii. Hematinics
  - iii. Leukocyte (WBC) Stimulants
  - iv. Platelet Aggregation Inhibitors
- h. Targeted Immunomodulators
- i. Topical Agents

- i. Dry Eye Disease or Keratoconjunctivitis
- ii. Miotics-Intraocular Pressure Reducers
- iii. Ophthalmic Antihistamines
- iv. Ophthalmic Anti-Inflammatory Agents
- v. Ophthalmic Mast Cell Stabilizers
- vi. Otic Preparations
- vii. Topical Anti-Inflammatory Agents-NSAIDs
- viii. Topical Antiparasitics
- ix. Topical Immunomodulators
- x. Topical Post-herpetic Neuralgia Agents

4. Public Comment

5. Other Business

6. Adjourn

---

## Microsoft Teams meeting

**Join on your computer, mobile app or room device**

[Click here to join the meeting](#)

Meeting ID: 239 471 212 774

Passcode: CoH8L2

[Download Teams](#) | [Join on the web](#)

**Join with a video conferencing device**

[425899727@t.plcm.vc](mailto:425899727@t.plcm.vc)

Video Conference ID: 111 949 407 82

[Alternate VTC instructions](#)

**Or call in (audio only)**

[+1 952-222-7450,,286466874#](tel:+19522227450,,286466874#) United States, Bloomington

Phone Conference ID: 286 466 874#

[Find a local number](#) | [Reset PIN](#)